KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation . Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently...
- Mechanism
- Curator reviewed
KAND567 is a small molecule Fractalkine receptor inhibitor with the ability to penetrate damaged tissue with poor blood flow. This drug has potential applications in the areas of cardiovascular disease, inflammatory diseases, and certain cancers. It is currently being investigated against inflammation and COVID-19.
- Formula / weight
- C19H25N5OS2 · 403.56 g/mol (avg)
- Also known as
- 1-Pentanol, 2-[[2-aMino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyriMidin-7-yl]aMino]-4-Methyl-, (2R)-
- Code names
- AZD 8797 · KAND567
Resolves to
ZMQSLMZOWVGBSM-GXTWGEPZSA-NSMILESCC(C)C[C@H](CO)NC1=NC(S[C@@H](C)C2=CC=CC=C2)=NC2=C1SC(N)=N2What you can answer from here — as of July 12, 2024
Which drugs share a target with KAND567, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account